Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
1.430
-0.050 (-3.38%)
Feb 19, 2026, 10:07 AM EST - Market open
Celularity Employees
Celularity had 123 employees as of December 31, 2024. The number of employees increased by 3 or 2.50% compared to the previous year.
Employees
123
Change (1Y)
3
Growth (1Y)
2.50%
Revenue / Employee
$329,902
Profits / Employee
-$655,667
Market Cap
41.24M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 123 | 3 | 2.50% |
| Dec 31, 2023 | 120 | -105 | -46.67% |
| Dec 31, 2022 | 225 | 0 | - |
| Dec 31, 2021 | 225 | 63 | 38.89% |
| Dec 31, 2020 | 162 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Aligos Therapeutics | 70 |
| Xilio Therapeutics | 64 |
| Jasper Therapeutics | 27 |
| PDS Biotechnology | 24 |
| INmune Bio | 22 |
| Veru Inc. | 20 |
| ABVC BioPharma | 19 |
CELU News
- 9 days ago - Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses - GlobeNewsWire
- 7 weeks ago - Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations - GlobeNewsWire
- 2 months ago - Celularity Announces Closing of Financing Transactions - GlobeNewsWire
- 2 months ago - Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision - GlobeNewsWire
- 4 months ago - Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care - GlobeNewsWire
- 4 months ago - Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - GlobeNewsWire
- 6 months ago - Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance - GlobeNewsWire
- 6 months ago - Celularity Receives Nasdaq Notice Regarding Form 10-Q - GlobeNewsWire